Stay updated
Sign up to receive the latest news and product updates from Autolus.
By clicking ‘Receive key updates’ you’re confirming that you agree with our Terms and conditions.
Aucatzyl is indicated for the treatment of adult patients (≥18 years) with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia.1
NICE recommends AUCATZYL to treat relapsed or refractory B-cell precursor acute lymphoblastic leukaemia in people aged ≥26 years in England, Wales and Northern Ireland.2,3
CAR=chimeric antigen receptor, NICE=National Institute for Health and Care Excellence.
Summary of Product Characteristics, Aucatzyl 2025.
NICE. Obecabtagene autoleucel for treating relapsed or refractory B-cell precursor acute lymphoblastic leukaemia. Issued December 2025. Accessed February 2026. https://www.nice.org.uk/guidance/ta1116/resources/obecabtagene-autoleucel-for-treating-relapsed-or-refractory-bcell-precursor-acute-lymphoblastic-leukaemia-pdf-2973530453903557.
AWTTC. Obecabtagene autoleucel (Aucatzyl®). Issued November 2025. Accessed February 2026. https://awttc.nhs.wales/accessing-medicines/medicine-recommendations/obecabtagene-autoleucel-aucatzyl/.
